After a decade of scant gains, some investors are now piling into pharmaceuticals as a combination of high yields and attractive valuations draw managers in, but is this the start of a decade-long move up?
Even in the context of their status as perennial cautious plays, drug companies have produced little in the way of capital growth over the past decade, particularly compared with some defensive peers....
To continue under same brands
Growth still strong and valuations attractive
Was CEO of TeamBlockchain
Joe McDonnell joins as head of portfolio solutions (EMEA)
Latest edition of the print magazine online